

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Upadacitinib for treating giant cell arteritis ID6299

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<u>Company</u>	General
 AbbVie (upadacitinib) 	All Wales Therapeutics and Toxicology
 <u>Patient/carer groups</u> Cardiovascular Care Partnership Circulation Foundation Heart UK Pumping Marvellous Foundation PMRGCA UK (Polymyalgia Rheumatica & Giant Cell Arteritis UK) Somerville Foundation South Asian Health Foundation Specialised Healthcare Alliance Vasculitis UK Versus Arthritis <u>Healthcare professional groups</u> British Association for Nursing in Cardiovascular Care British Cardiovascular Intervention 	 Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 Society British Cardiovascular Society British Geriatrics Society British Society of Cardiovascular Imaging British Society of Rheumatology Royal College of General Practitioners Royal College of Nursing Royal College of Ophthalmologists Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society of Vascular Nurses UK Clinical Pharmacy Association 	 Possible comparator companies Roche (tocilizumab) Relevant research groups British Society for Cardiovascular Research Cochrane Heart Group Genomics England MRC Clinical Trials Unit National Centre for Cardiovascular Preventions and Outcomes Heart Research UK National Institute for Health Research The Society for Research in
 OK Clinical Flamacy Association Vascular Society of Great Britain and Ireland 	 Rehabilitation Wellcome Trust

Provisional stakeholder list for the evaluation of upadacitinib for treating giant cell arteritis ID6299 Issue date: January 2025

© National Institute for Health and Care Excellence 2025. All rights reserved.



Consultees	Commentators (no right to submit or appeal)
Others	Associated Public Health groups
• Department of Health and Social Care	Public Health Wales
NHS England	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.